Schering Hunting Biotech Deals To Complement Specialty Portfolio

Schering-Plough is focusing its in-licensing activities on specialty biotechnology products, CEO Fred Hassan told analysts during the company's business review in New York City Nov. 18

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet